Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E37.98 EPS (ttm)1.53 Insider Own0.03% Shs Outstand2.92B Perf Week-0.07%
Market Cap169.82B Forward P/E16.00 EPS next Y3.63 Insider Trans27.85% Shs Float2.91B Perf Month-0.67%
Income4.52B PEG9.55 EPS next Q0.81 Inst Own75.80% Short Float1.18% Perf Quarter1.82%
Sales43.63B P/S3.89 EPS this Y-26.50% Inst Trans0.06% Short Ratio3.82 Perf Half Y14.91%
Book/sh17.03 P/B3.41 EPS next Y4.58% ROA5.70% Target Price60.94 Perf Year25.35%
Cash/sh7.02 P/C8.28 EPS next 5Y3.98% ROE12.60% 52W Range43.54 - 59.65 Perf YTD17.89%
Dividend1.76 P/FCF33.10 EPS past 5Y-16.50% ROI6.60% 52W High-2.60% Beta0.40
Dividend %3.03% Quick Ratio1.60 Sales past 5Y13.00% Gross Margin58.50% 52W Low33.43% ATR0.73
Employees77300 Current Ratio1.80 Sales Q/Q-3.80% Oper. Margin15.10% RSI (14)50.99 Volatility1.09% 1.33%
OptionableYes Debt/Eq0.56 EPS Q/Q9.60% Profit Margin14.00% Rel Volume0.66 Prev Close58.11
ShortableYes LT Debt/Eq0.39 EarningsJul 29 BMO Payout83.20% Avg Volume8.98M Price58.10
Recom2.40 SMA20-0.39% SMA500.80% SMA2009.74% Volume4,991,708 Change-0.02%
30-Apr-14Reiterated Argus Buy $62 → $66
11-Apr-14Reiterated MKM Partners Buy $64 → $70
05-Feb-14Reiterated Argus Buy $54 → $62
14-Jan-14Reiterated MKM Partners Buy $59 → $64
03-Jun-13Reiterated MKM Partners Buy $54 → $59
15-Apr-13Reiterated Barclays Overweight $45 → $60
04-Feb-13Reiterated MKM Partners Buy $51 → $52
04-Feb-13Reiterated Barclays Overweight $46 → $45
20-Nov-12Upgrade MKM Partners Neutral → Buy $47 → $51
17-Oct-12Reiterated MP Advisors Outperform $45 → $50
30-Jul-12Reiterated UBS Buy $45 → $50
13-Jul-12Upgrade MP Advisors Market Perform → Outperform $45
03-Feb-12Reiterated Barclays Capital Overweight $38 → $40
03-Feb-12Downgrade MKM Partners Buy → Neutral $42 → $40
29-Nov-11Initiated MKM Partners Buy $38
14-Sep-11Reiterated Barclays Capital Overweight $41 → $38
16-May-11Reiterated UBS Buy $40 → $42
04-Feb-11Reiterated UBS Buy $42 → $40
24-Jan-11Reiterated Deutsche Bank Buy $48 → $43
24-Jan-11Reiterated Barclays Capital Overweight $43 → $41
24-Jul-14 02:02PM  Keep Calm and Carry On, Roche Stock at Motley Fool
11:25AM  Gilead Sciences Q2 2014: All Is Good, More To Come At Medical Conferences Later This Year at Seeking Alpha
09:23AM  [video] Cramer's Mad Dash: GILD bounces at CNBC
08:30AM  Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients Business Wire
12:01AM  Patient Cures Spur Demand for $1,000 Hepatitis C Pill Bloomberg
12:01AM  Patient Cures Spur Demand for $1,000 Hepatitis C Pill at Bloomberg
23-Jul-14 10:15PM  Merck & Co. Inc.: I'm Long, But It Screams Overvalued Today at Seeking Alpha
04:19PM  Is Inovio Undervalued After Positive HPV Therapy Results? at Seeking Alpha
12:15PM  Merck Announces Fourth-Quarter 2014 Dividend Business Wire
22-Jul-14 05:02PM  3 Things You Need to Watch on Gilead Sciences Inc. Earnings Call at Motley Fool
06:13AM  [$$] 9 Health Care Stocks From Index-Crushing Fund at Barrons.com
05:52AM  Bad Times Continue To Hit Merck's Animal Health Segment at Seeking Alpha
21-Jul-14 01:03PM  ABBV, MRK And PFE, Pushing Health Care Sector Downward at TheStreet
10:38AM  Gilead Sciences: Sovaldi's a Blockbuster, the Question is How Big at Barrons.com
09:53AM  5 More Possible Partners For MannKind's Afrezza, Each With A Strong Diabetes Care Franchise at Seeking Alpha
20-Jul-14 10:10AM  Gilead Drug Combination Cures Hepatitis C in HIV Patients Bloomberg
10:10AM  Gilead Drug Combination Cures Hepatitis C in HIV Patients at Bloomberg
18-Jul-14 09:06PM  How the Dow's Pharma Stocks Helped Boost Markets Friday at Motley Fool
11:29AM  3 Stocks Reiterated As A Buy: MU, MRK, MET at TheStreet
17-Jul-14 08:30AM  Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment PR Newswire
16-Jul-14 07:53PM  Studies see new risks for cholesterol drug niacin AP
06:11PM  Studies see new risks for cholesterol drug niacin AP
11:09AM  Jim Cramer's Stop Trading: Speculation Isn't Bad at TheStreet
06:21AM  Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14) at Seeking Alpha
15-Jul-14 03:02PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
12:51PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
12:34PM  Heres why Congress lets U.S. companies dodge taxes Yahoo Finance
12:33PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
11:13AM  Perrigo retreats after analyst sees limited potential buyers at theflyonthewall.com
10:49AM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
10:20AM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
08:17AM  Tax Reform, Not Tax Inversions, Will Rescue The U.S. Pharma, Bio, And Medical-Device Industries at Forbes
12:12AM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
14-Jul-14 11:07PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
09:20PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
08:00PM  [$$] Merck Pushes to Revive Beef Drug at The Wall Street Journal
05:01PM  1 Hidden Blockbuster Lurking in Merck's Pipeline? at Motley Fool
07:02AM  Johnson & Johnson Earnings: Can Pharma Keep Stoking Growth? at Motley Fool
11-Jul-14 02:00PM  A Global Pharma Boom Is Coming... Here's How To Profit StreetAuthority Network
11:35AM  Senators Ask Gilead To Explain Sovaldi Pricing at Investor's Business Daily
08:52AM  How Gilead Sciences Can Deliver A Double: Part Two at Forbes
08:16AM  If Big Pharma Ignores Antibacterial R&D, Where Will We Get The Drugs To Treat Superbugs? at Forbes
10-Jul-14 06:30PM  Dengue Vaccine Shows Promise Against 3 Out of 4 Viruses at Bloomberg
02:02PM  Jounce Taps Merck Vet to Lead Cancer Drug Push at Motley Fool
10:24AM  Bristol-Myers Seeking Nivolumab Approval In Melanoma at Investor's Business Daily
08:26AM  Pharma's Poor Reputation Doesn't Help In The Fight Against Superbugs at Forbes
08-Jul-14 04:34PM  Study Shows No Link Between Gardasil And Blood Clots at Forbes
12:34PM  Why These Dow "Dogs" Are Soaring in 2014 at Motley Fool
07-Jul-14 07:01PM  Study paves the way for a blood test to predict Alzheimer's Reuters
05:46PM  Merck Says It Regrets Strong-Arming Italian Researcher at Forbes
03:11PM  [$$] Novartis Leukemia Treatment Gets 'Breakthrough' Status at The Wall Street Journal
02:58PM  [$$] Novartis Leukemia Treatment Gets 'Breakthrough' Status at The Wall Street Journal
09:12AM  Make Your Move TheStreet
06-Jul-14 03:19PM  Merck Uses Legal Threats To Stifle Negative Advice About Zetia And Vytorin In Italy at Forbes
03-Jul-14 05:08PM  A Primer On The Hepatitis C Market Investor's Business Daily
05:08PM  A Primer On The Hepatitis C Market Drugmakers are racing to market, but pricing and what comes after the cure raise doubts Investor's Business Daily
03:25PM  Vaccine Refusal Myths Drive Up Development Costs, Prices at Forbes
09:39AM  Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline Benzinga
02-Jul-14 06:08PM  Cramer: Is Dow 17,000 the bull's last stop? at CNBC
06:00PM  [video] 5 stocks propelling the Dow at CNBC
05:07PM  Januvia Linked To Increase in Heart Failure Hospitalizations at Forbes
02:03PM  Why Are These 3 Dow Jones Stocks Crushing the Market in 2014? at Motley Fool
01:54PM  US stocks hover around flat line, stocks struggle to hold gains at CNBC
01:16PM  US stocks hover around flat line, Dow nears 17,000 at CNBC
12:36PM  Why Thousands Of Men Like JPMorgan CEO Jamie Dimon Are Getting Throat Cancer at Forbes
11:34AM  No Perfect Prescription: Barclays Downgrades Bristol-Myers, Upgrades AbbVie at Barrons.com
11:34AM  No Perfect Prescription: Barclays Cuts Bristol-Myers, Upgrades AbbVie at Barrons.com
10:37AM  Start-up gives dogs' tags an upgrade at CNBC
03:32AM  Merck: Buy The Dip... But Not Yet at Seeking Alpha
01-Jul-14 12:09PM  Isis - Addressing Some Of The Bull Arguments To My Short Thesis at Seeking Alpha
12:00PM  Will Merck's Anti-PD-1 Therapy be the First to Launch? Zacks
09:50AM  Bayer broadens healthcare line by keeping Merck's consumer brands Reuters
09:12AM  Physicians Interactive CEO Looks for Acquisitions at TheStreet
08:38AM  Why Merck Should Buy Inovio, Seattle Genetics, or MannKind at Motley Fool
07:55AM  The Five Best Performing DJIA Stocks of 2014 at 24/7 Wall St.
07:54AM  Bayer broadens healthcare line by keeping Merck's consumer brands Reuters
30-Jun-14 09:36PM  Self-Destructing Mosquitoes to Help Brazil Fight Deadly Dengue Bloomberg
09:27PM  Why Investors are Wrong about Gilead at Motley Fool
01:54PM  Self-Destructing Mosquitoes to Help Brazil Fight Deadly Dengue Bloomberg
12:13PM  Midday movers: Allergan, MBIA, Treehouse Foods & More at CNBC
09:17AM  Mondays Top Biotech Stories: MannKind, Dicerna, Flamel, and Merck at Motley Fool
08:22AM  Merck nausea drug works in children in late-stage trial Reuters
08:00AM  Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy Business Wire
06:00AM  MSDs Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma Business Wire
06:00AM  Mercks Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma Business Wire
27-Jun-14 06:30PM  What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck? at Seeking Alpha
06:30PM  What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck?
05:16PM  [video] Biotech and pharma sector outlook at CNBC
05:16PM  [video] Biotech and pharma sector outlook
05:02PM  Should Dividend Investors Eject Merck & Co., Inc? at Motley Fool
05:02PM  Should Dividend Investors Eject Merck & Co., Inc?
03:49PM  Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly Benzinga
03:49PM  Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly
12:17PM  [video] Best time to buy Celgene, Vertex & more at CNBC
12:17PM  [video] Best time to buy Celgene, Vertex & more
08:40AM  Up and Down the Ladder.. The Latest Comings and Goings at Merck, Actavis and.. at The Wall Street Journal
08:40AM  Up and Down the Ladder.. The Latest Comings and Goings at Merck, Actavis and..
05:00AM  Stallergenes: An Unknown, Predictable Biotech With 50% Upside
26-Jun-14 10:23AM  Closer Look at Gilead's Slowing Hep C Prescriptions
08:00AM  Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals PR Newswire
Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company's Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company's Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM
Deese Willie AExe V-P & Pres. MMDJun 27Option Exercise27.8572,2902,013,164178,512Jun 30 04:23 PM
Deese Willie AExe V-P & Pres. MMDJun 27Sale58.2672,2904,211,254106,222Jun 30 04:23 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 14Sale55.9110,527588,5840May 14 02:48 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Option Exercise34.2012,876440,307345,927May 13 03:56 PM
FRAZIER KENNETH CChairman, President & CEOMay 09Sale55.0010,220562,100335,707May 13 03:56 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 04Option Exercise0.0019,147019,147May 06 04:03 PM
Golestani ClarkEVP & Chief Info OfficerMay 04Option Exercise0.002,05109,278May 06 04:02 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 04Option Exercise0.009,300098,387May 06 04:02 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareMay 04Option Exercise0.005,470038,311May 06 04:02 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise0.004,240011,999May 06 04:02 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise0.009,8470132,660May 06 04:02 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 04Option Exercise0.004,103026,720May 06 04:02 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 04Option Exercise0.004,103020,828May 06 04:01 PM
Deese Willie AExe V-P & Pres. MMDMay 04Option Exercise0.007,6590109,671May 06 04:01 PM
FRAZIER KENNETH CChairman, President & CEOMay 04Option Exercise0.0041,0280351,522May 06 04:01 PM
HARRISON WILLIAM B JRDirectorApr 25Option Exercise47.235,000236,1506,400Apr 29 11:36 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Option Exercise34.2012,876440,307320,541Apr 11 09:53 AM
FRAZIER KENNETH CChairman, President & CEOApr 10Sale57.2410,047575,108310,494Apr 11 09:53 AM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Option Exercise39.90145,2255,794,929267,070Apr 04 05:07 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 04Sale56.43145,2258,195,164121,845Apr 04 05:07 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Option Exercise48.246,375307,53012,036Feb 14 05:11 PM
Golestani ClarkEVP & Chief Info OfficerFeb 14Sale55.475,990332,2766,046Feb 14 05:11 PM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Option Exercise36.5649,7501,818,86071,457Feb 14 11:17 AM
Heller Bridgette PExe.VP & Pres.Con.Hlth.CareFeb 13Sale55.0443,8702,414,57027,587Feb 14 11:17 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Option Exercise48.2410,000482,40020,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Option Exercise48.2445,0002,170,800304,349Feb 11 05:34 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Option Exercise47.6518,000857,70518,000Feb 13 10:12 AM
Schechter Adam HEVP & Pres-Global Human HealthFeb 11Sale55.6118,0001,000,9350Feb 13 10:12 AM
Canan JohnSr.V-P Finc-Global ControllerFeb 11Sale55.7010,000557,00210,697Feb 11 05:07 PM
FRAZIER KENNETH CChairman, President & CEOFeb 11Sale54.5241,5202,263,683262,829Feb 11 05:34 PM
WEEKS WENDELL PDirectorFeb 10Option Exercise47.235,000236,1505,100Feb 11 03:41 PM
WENDELL PETER CDirectorFeb 10Option Exercise47.235,000236,1506,000Feb 11 03:48 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Option Exercise48.2420,000964,800156,049Feb 11 03:54 PM
Deese Willie AExe V-P & Pres. MMDFeb 10Sale54.6850,0002,734,155106,049Feb 11 03:54 PM
WENDELL PETER CDirectorFeb 10Sale54.445,000272,1931,000Feb 11 03:48 PM
WEEKS WENDELL PDirectorFeb 10Sale54.265,000271,283100Feb 11 03:41 PM
Deese Willie AExe V-P & Pres. MMDJan 27Option Exercise47.7930,0001,433,700136,049Jan 28 10:09 AM